{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:28:27Z","timestamp":1792218507796,"version":"4.4.0"},"reference-count":90,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["20-43-01004"],"award-info":[{"award-number":["20-43-01004"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["075-15-2022-1118"],"award-info":[{"award-number":["075-15-2022-1118"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004569","name":"Ministry of Science and the Higher Education of RF","doi-asserted-by":"publisher","award":["20-43-01004"],"award-info":[{"award-number":["20-43-01004"]}],"id":[{"id":"10.13039\/501100004569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004569","name":"Ministry of Science and the Higher Education of RF","doi-asserted-by":"publisher","award":["075-15-2022-1118"],"award-info":[{"award-number":["075-15-2022-1118"]}],"id":[{"id":"10.13039\/501100004569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Antimetabolites of folic acid represent a large group of drugs and drug candidates, including those for cancer chemotherapy. In this current review, the most common methods and approaches are presented for the synthesis of therapeutically significant antimetabolites of folic acid, which are Methotrexate (MTX), Raltitrexed (Tomudex, ZD1694), Pralatrexate, Pemetrexed, TNP-351, and Lometrexol. In addition, the applications or uses of these folic acid antimetabolites are also discussed.<\/jats:p>","DOI":"10.3390\/molecules27196229","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T05:33:14Z","timestamp":1663824794000},"page":"6229","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Folic Acid Antimetabolites (Antifolates): A Brief Review on Synthetic Strategies and Application Opportunities"],"prefix":"10.3390","volume":"27","author":[{"given":"Igor S.","family":"Kovalev","sequence":"first","affiliation":[{"name":"Department of Organic & Biomolecular Chemistry, Ural Federal University, 620002 Yekaterinburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grigory V.","family":"Zyryanov","sequence":"additional","affiliation":[{"name":"Department of Organic & Biomolecular Chemistry, Ural Federal University, 620002 Yekaterinburg, Russia"},{"name":"I. Ya. Postovskiy Institute of Organic Synthesis, Ural Branch, Russian Academy of Sciences, 620219 Yekaterinburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sougata","family":"Santra","sequence":"additional","affiliation":[{"name":"Department of Organic & Biomolecular Chemistry, Ural Federal University, 620002 Yekaterinburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adinath","family":"Majee","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Visva-Bharati (A Central University), Santiniketan 731235, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7997-3686","authenticated-orcid":false,"given":"Mikhail V.","family":"Varaksin","sequence":"additional","affiliation":[{"name":"Department of Organic & Biomolecular Chemistry, Ural Federal University, 620002 Yekaterinburg, Russia"},{"name":"I. Ya. Postovskiy Institute of Organic Synthesis, Ural Branch, Russian Academy of Sciences, 620219 Yekaterinburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9140-358X","authenticated-orcid":false,"given":"Valery N.","family":"Charushin","sequence":"additional","affiliation":[{"name":"Department of Organic & Biomolecular Chemistry, Ural Federal University, 620002 Yekaterinburg, Russia"},{"name":"I. Ya. Postovskiy Institute of Organic Synthesis, Ural Branch, Russian Academy of Sciences, 620219 Yekaterinburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0163-7258(90)90094-I","article-title":"Metabolism and action of amino acid analog anti-cancer agents","volume":"46","author":"Ahluwalia","year":"1990","journal-title":"Pharmacol. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"200004","DOI":"10.1098\/rsob.200004","article-title":"Anti-cancer peptides: Classification, mechanism of action, reconstruction and modification","volume":"10","author":"Xie","year":"2020","journal-title":"Open Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3892\/ijo.2020.5099","article-title":"Anticancer peptide: Physicochemical property, functional aspect and trend in clinical application (Review)","volume":"57","author":"Chiangjong","year":"2020","journal-title":"Int. J. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1021\/jm2000882","article-title":"Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3","volume":"54","author":"Mandal","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0065-2725(08)60526-7","article-title":"Aza Analogs of Pyrimidine and Purine Bases of Nucleic Acids","volume":"1","author":"Gut","year":"1963","journal-title":"Adv. Heterocycl. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Gojkovic, Z., and Karlsson, A. (2007). Purine and Pyrimidine-Based Analogs and Suicide Gene Therapy. Deoxynucleoside Analogs in Cancer Therapy, Humana Press.","DOI":"10.1007\/978-1-59745-148-2_16"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/cbic.201500072","article-title":"Antivitamins for medicinal applications","volume":"16","author":"Zelder","year":"2015","journal-title":"ChemBioChem"},{"key":"ref_8","unstructured":"Howell, A. (1990). The Role of Antihormones, CRC Press."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Albert, A. (1985). Antimetabolites: Antagonistic analogues of coenzymes and enzyme substrates. Selective Toxicity, Springer.","DOI":"10.1007\/978-94-009-4846-4_9"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1684\/bdc.2011.1476","article-title":"Les antim\u00e9tabolites","volume":"98","author":"Lansiaux","year":"2011","journal-title":"Bull. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1152\/physrev.1952.32.2.197","article-title":"Folic acid antagonists","volume":"32","author":"Petering","year":"1952","journal-title":"Physiol. Rev."},{"key":"ref_12","first-page":"79","article-title":"Treating Cancer with Antimetabolites","volume":"62","author":"Ellison","year":"1962","journal-title":"Am. J. Nurs."},{"key":"ref_13","first-page":"45","article-title":"Methotrexate, an antimetabolite of folic acid, a brief throwback","volume":"26","author":"Panderi","year":"2014","journal-title":"Pharmakeftiki"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"8470","DOI":"10.1016\/S0021-9258(19)38912-4","article-title":"Mechanism of thymidylate synthase inhibition by methotrexate in human neoplastic cell lines and normal human myeloid progenitor cells","volume":"265","author":"Chu","year":"1990","journal-title":"J. Biol. Chem."},{"key":"ref_15","unstructured":"Chabner, B., and Longo, D. (2001). Antifolates. Cancer Chemotherapy and Biotherapy, L. Williams & W."},{"key":"ref_16","first-page":"1116","article-title":"Ly231514, a pyrrolo [2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes","volume":"57","author":"Shih","year":"1997","journal-title":"Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Avenda\u00f1o, C., and Men\u00e9ndez, J.C. (2008). Antimetabolites. Medicinal Chemistry of Anticancer Drugs, Elsevier.","DOI":"10.1016\/B978-0-444-52824-7.00002-0"},{"key":"ref_18","first-page":"65","article-title":"Folate antimetabolites inhibitory to de novo purine synthesis","volume":"Volume 58","author":"Muggia","year":"1991","journal-title":"New Drugs, Concepts and Results in Cancer Chemotherapy. Cancer Treatment and Research"},{"key":"ref_19","unstructured":"Catalucci, E. (1991). Process for the Production of Methotrexate. (US4224446A), U.S. Patent."},{"key":"ref_20","unstructured":"Bin, Y., Shubin, W., Zhichao, M., Quansheng, S., Yanjiao, X., and Lilian, L. (2019). A Kind of Preparation Method of Methotrexate (MTX). (CN109553619A), U.S. Patent."},{"key":"ref_21","unstructured":"Piper, J.R., and Montgomery, J.A. (1978). 6-(Bromomethyl)-2,4-diaminopteridine Hydrobromide. (US4077957A), U.S. Patent."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"10004","DOI":"10.1021\/ja971568j","article-title":"Efficient syntheses of pyrofolic acid and pteroyl azide, reagents for the production of carboxyl-differentiated derivatives of folic acid","volume":"119","author":"Luo","year":"1997","journal-title":"J. Am. Chem. Soc."},{"key":"ref_23","unstructured":"Attoline, E., Michieletti, M., Rossi, D., and Allegrini, P. (1988). Process for the Preparation of Pteridine Derivatives. (US4767859), U.S. Patent."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3987\/S-1987-01-0507","article-title":"Synthesis of multi-13C-enriched methotrexate for NMR studies of drug-Enzyme interactions","volume":"25","author":"Cheung","year":"1987","journal-title":"Heterocycles"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3987\/COM-88-S142","article-title":"N-(L-\u03b1-aminoacyl) derivatives of methotrexate","volume":"28","author":"Cheung","year":"1989","journal-title":"Heterocycles"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.bmc.2011.12.020","article-title":"A photochemical approach for controlled drug release in targeted drug delivery","volume":"20","author":"Choi","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"ref_27","unstructured":"Lei, T., Yi, Z., Jianta, W., Gaofeng, Z., and Xing, C. (2021). Synthesis Process of Methotrexate. (CN112851676A), U.S. Patent."},{"key":"ref_28","unstructured":"Wiecko, J. (1976). Process for Preparing Methotrexate or an N-Substituted Derivative Thereof and\/or a di (lower) Alkyl Ester Thereof and Precursor Therefor. (US4057548A), U.S. Patent."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1021\/ja01173a061","article-title":"Analogs of Pteroylglutamic Acid. III. 4-Amino Derivatives","volume":"71","author":"Seeger","year":"1949","journal-title":"J. Am. Chem. Soc."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s002800051116","article-title":"The plasma pharmacokinetics and cerebrospinal fluid penetration of the thymidylate synthase inhibitor raltitrexed (Tomudex(TM)) in a nonhuman primate model","volume":"44","author":"Widemann","year":"1999","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.clinre.2013.11.006","article-title":"Raltitrexed-based chemotherapy for advanced colorectal cancer","volume":"38","author":"Liu","year":"2014","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1200\/JCO.1998.16.9.2943","article-title":"Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group","volume":"16","author":"Cocconi","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1021\/jm00109a011","article-title":"Quinazoline Antifolate Thymidylate Synthase Inhibitors: Heterocyclic Benzoyl Ring Modifications","volume":"34","author":"Marsham","year":"1991","journal-title":"J. Med. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1081\/SCC-120024732","article-title":"New synthesis of thymidylate synthase inhibitor raltitrexed","volume":"33","author":"Cao","year":"2003","journal-title":"Synth. Commun."},{"key":"ref_35","unstructured":"Yao, T., Zubing, W., Shuwang, G., Jian, W., Yuzhu, C., Feng, L., Dan, X., Chunxia, Z., and Zhoushan, T. (2017). The Formoxyl of 5-((Alkoxy methylene)amino)thienyl-2-formyl Group)-L-glutamic Acid Dialkyl Ester and Preparation Method Thereof. (CN106957296A), U.S. Patent."},{"key":"ref_36","unstructured":"Xiqun, J., Wei, W., Zhoushan, T., Jun, H., Jing, W., Yuzhu, C., Huaping, W., Dan, X., Chunxia, Z., and Chuanjun, W. (2018). A kind of Pharmaceutical Composition of Raltitrexed Pharmaceutical Composition and Preparation Method Thereof. (CN107616976A), U.S. Patent."},{"key":"ref_37","unstructured":"Shaojie, H., Wei, S., Zhaobai, Z., and Xu, S. (2019). Preparation Method of Raltitrexed. (CN110551114A), U.S. Patent."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: Results from the pivotal PROPEL study","volume":"29","author":"Pro","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2017-09-806737","article-title":"A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma","volume":"131","author":"Amengual","year":"2018","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2217\/fon.12.168","article-title":"Pralatrexate: Treatment of T-cell non-Hodgkin\u2019s lymphoma","volume":"9","author":"Parker","year":"2012","journal-title":"Future Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1021\/jm00067a020","article-title":"Synthesis and Antitumor Activity of 10-Propargyl-10-deazaaminopterin","volume":"36","author":"DeGraw","year":"1993","journal-title":"J. Med. Chem."},{"key":"ref_42","unstructured":"Guimin, Z., Chengfu, C., and Chuanbing, W. (2020). A Kind of Preparation Method of Pralatrexate. (CN108069970), U.S. Patent."},{"key":"ref_43","unstructured":"Giust, W., Burton, R., Gorin, B., and Clayton, J. (2013). Process for Preparation of an Antifolate Agent. (WO2013\/177713A1), U.S. Patent."},{"key":"ref_44","unstructured":"O\u2019Connor, O.A., and Sirotnak, F.M. (2005). Treatment of T-Cell Lymphoma Using 10-Propargyl-10-Deazaaminopterin. (US2005\/267117A1), U.S. Patent."},{"key":"ref_45","unstructured":"Lahiri, S., Gupta, N., Singh, H.K., Panda, N., Handa, V., Abul, A., Gupta, C.K., Sanghani, S., and Sonavane, G.M. (2016). Process for the Preparation of Pralatrexate. (US9440979B2), U.S. Patent."},{"key":"ref_46","unstructured":"Lahiri, S., Gupta, N., and Singh, H.K. (2014). Salts of Pralatrexate. (WO2014\/20553A1), U.S. Patent."},{"key":"ref_47","unstructured":"Lahiri, S., Gupta, N., Singh, H.K., Panda, N., Handa, V., Abul, A., Gupta, C.K., Sanghani, S., and Sonavane, G.M. (2014). Improved Process for the Preparation of Pralatrexate. (WO2014016740A2), U.S. Patent."},{"key":"ref_48","unstructured":"Tiseni, P.S., Galluzzo, C., Canavesi, A., and Biljan, T. (2013). Processes and Intermediates for Preparing Pralatrexate. (EP2794610B1), U.S. Patent."},{"key":"ref_49","unstructured":"Pronk, G.J. (2011). Optically Pure Diastereomers of 10-Propargyl-10-Deazaaminopterin and Methods of Using Same. (US8835433B2), U.S. Patent."},{"key":"ref_50","unstructured":"Alla, R.R.V., Ramarao, C., Michel, P.T., Nitlikar, L.H., Kalam, B.R., and Duduka, R. (2013). A Process for Preparing Intermediates of 10-propargyl-10-deazaaminopterin (pralatrexate) Synthesis and the Intermediates Thereof. (WO2013164856A1), U.S. Patent."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1634\/theoncologist.2009-0092","article-title":"Approval Summary: Pemetrexed in the Initial Treatment of Advanced\/Metastatic Non-Small Cell Lung Cancer","volume":"14","author":"Cohen","year":"2009","journal-title":"Oncologist"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.lungcan.2009.06.006","article-title":"Pemetrexed in the treatment of advanced non-squamous lung cancer","volume":"66","author":"Rossi","year":"2009","journal-title":"Lung Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus Chemotherapy in Metastatic Non\u2013Small-Cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1093\/jnci\/djk222","article-title":"Cisplatin versus carboplatin for patients with metastatic non-small-cell lung cancer\u2013an old rivalry renewed","volume":"99","author":"Azzoli","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0093-7754(03)00283-5","article-title":"Pemetrexed (alimta, MTA, multitargeted antifolate, LY231514) for malignant pleural mesothelioma","volume":"30","author":"Manegold","year":"2003","journal-title":"Semin. Oncol."},{"key":"ref_56","first-page":"2677","article-title":"Pharmacokinetic and Pharmacodynamic Evaluation of the Glycinamide Ribonucleotide Formyltransferase Inhibitor AG20341","volume":"6","author":"McLeod","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1021\/jo00059a016","article-title":"A Novel Synthetic Approach to Pyrrolo [2,3-d]pyrimidine Antifolates","volume":"58","author":"Miwa","year":"1993","journal-title":"J. Org. Chem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"10016","DOI":"10.1021\/jm401328u","article-title":"Discovery of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis","volume":"56","author":"Wang","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_59","unstructured":"Bonaccorsi, F., Calvani, F., and Pasqui, F. (2014). Process for the Preparation of Pemetrexed and Lysin Salt Thereof. (EP2882753B1), U.S. Patent."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"10004","DOI":"10.3390\/molecules200610004","article-title":"Synthesis and physicochemical characterization of the impurities of pemetrexed disodium, an anticancer drug","volume":"20","author":"Michalak","year":"2015","journal-title":"Molecules"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1016\/S0040-4039(99)00676-0","article-title":"A simple and concise synthesis of LY231514 (MTA)","volume":"40","author":"Taylor","year":"1999","journal-title":"Tetrahedron Lett."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"9938","DOI":"10.1021\/jo030248h","article-title":"A New and Efficient Synthesis of Pyrrolo[2,3-d]pyrimidine Anticancer Agents: Alimta (LY231514, MTA), Homo-Alimta, TNP-351, and Some Aryl 5-Substituted Pyrrolo[2,3-d]pyrimidines","volume":"68","author":"Taylor","year":"2003","journal-title":"J. Org. Chem."},{"key":"ref_63","unstructured":"Taylor, E.C., and Liu, B. (2000). Process for the Preparation of pyrrolo[2,3-d]pyrimidines. (US6066732 A), U.S. Patent."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1021\/jm00101a023","article-title":"A Dideazatetrahydrofolate Analogue Lacking a Chiral Center at C-6, N-[4-[2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5yl)ethyl[benzoyl]-l-glutamic Acid is an Inhibitor of Thymidylate Synthase","volume":"35","author":"Taylor","year":"1992","journal-title":"J. Med. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1016\/S0040-4039(99)00959-4","article-title":"A novel synthetic route to 7-substituted derivatives of the antitumor agent LY231514 (MTA)","volume":"40","author":"Taylor","year":"1999","journal-title":"Tetrahedron Lett."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41586-021-03448-9","article-title":"Skeletal editing through direct nitrogen deletion of secondary amines","volume":"593","author":"Kennedy","year":"2021","journal-title":"Nature"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/BF00686032","article-title":"Novel pyrrolo[2,3-d]pyrimidine antifolate TNP-351: Cytotoxic effect on methotrexate-resistant CCRF-CEM cells and inhibition of transformylases of de novo purine biosynthesis","volume":"34","author":"Itoh","year":"1994","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1021\/jm00106a012","article-title":"Novel pyrrolo [2, 3-d] pyrimidine antifolates: Synthesis and antitumor activities","volume":"34","author":"Miwa","year":"1991","journal-title":"Med. Chem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"6687","DOI":"10.1038\/sj.onc.1204088","article-title":"New agents in cancer clinical trials","volume":"19","author":"Adams","year":"2000","journal-title":"Oncogene"},{"key":"ref_70","first-page":"74","article-title":"Clinical pharmacokinetics of antitumor antifolates","volume":"26","author":"Newell","year":"1999","journal-title":"Semin. Oncol."},{"key":"ref_71","first-page":"5236","article-title":"Antifolates targeting purine synthesis allow entry of tumor cells into S phase regardless of p53 function","volume":"62","author":"Bronder","year":"2002","journal-title":"Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1021\/jm00145a012","article-title":"Synthesis of the Antileukemic Agents 5, 10-Dideazaaminopterin and 5, 10-Dideaza-5, 6, 7, 8-tetrahydroaminopterin","volume":"28","author":"Taylor","year":"1985","journal-title":"J. Med. Chem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.3987\/COM-88-4597","article-title":"Diels-Alder reactions of 6-azapterins. An alternative strategy for the synthesis of 5,10-dideaza-5,6,7,8-tetrahydrofolic acid (DDATHF)","volume":"27","author":"Taylor","year":"1988","journal-title":"Heterocycles"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1021\/jo00276a023","article-title":"Convergent and Efficient Palladium-Effected Synthesis of 5,10-Dideaza-5,6,7,8-tetrahydrofolic Acid (DDATHF)","volume":"54","author":"Taylor","year":"1989","journal-title":"J. Org. Chem."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0003-9861(88)90369-4","article-title":"Synthesis and biological properties of 5,10-dideaza-5,6,7,8-tetrahydrofolic acid","volume":"265","author":"Boschelli","year":"1988","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1021\/jm00119a018","article-title":"Synthesis and Antifolate Activity of 5-Methyl-5,10-dideaza Analogues of Aminopterin and Folic Acid and an Alternative Synthesis of 5,10-Dideazatetrahydrofolic Acid, a Potent Inhibitor of Glycinamide Ribonucleotide Formyltransferase","volume":"31","author":"Piper","year":"1988","journal-title":"J. Med. Chem."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/BF00194531","article-title":"A simplified and efficient synthesis of 5,10-dideaza-5,6,7,8-tetrahydrofolic acid (DDATHF)","volume":"14","author":"Taylor","year":"1996","journal-title":"Investig. New Drugs"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1039\/b505907k","article-title":"Synthesis of (6R)- and (6S)-5,10-dideazatetrahydrofolate oligo-\u03b3-glutamates: Kinetics of multiple glutamate ligations catalyzed by folylpoly-\u03b3-glutamate synthetase","volume":"3","author":"Tomsho","year":"2005","journal-title":"Org. Biomol. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.1016\/S0040-4039(01)93875-4","article-title":"Asymmetric synthesis and absolute configuration of 5,10-dideaza-5,6,7,8-tetrahydropteroic acid and 5,10-dideaza-5,6,7,8-tetrahydrofolic acid (DDATHF)","volume":"30","author":"Barnett","year":"1989","journal-title":"Tetrahedron Lett."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"7038","DOI":"10.1021\/jo00102a031","article-title":"Asymmetric Synthesis of Lometrexol ((6R)-5,10-Dideaza-5,6,7,8-tetrahydrofolic Acid)","volume":"59","author":"Barnett","year":"1994","journal-title":"J. Org. Chem."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1021\/jm0303352","article-title":"Target Guided Synthesis of 5-Benzyl-2,4-diamonopyrimidines: Their Antimalarial Activities and Binding Affinities to Wild Type and Mutant Dihydrofolate Reductases from Plasmodium falciparum","volume":"47","author":"Sirichaiwat","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3201\/eid0605.000503","article-title":"Toxin gene expression by Shiga toxin-producing Escherichia coli: The role of antibiotics and the bacterial SOS response","volume":"6","author":"Kimmitt","year":"2000","journal-title":"Emerg. Infect. Dis."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/prot.22383","article-title":"Structural comparison of chromosomal and exogenous dihydrofolate reductase from Staphylococcus aureus in complex with the potent inhibitor trimethoprim","volume":"76","author":"Heaslet","year":"2009","journal-title":"Proteins Struct. Funct. Bioinforma."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2165\/00003495-198223060-00001","article-title":"Trimethoprim: A Review of its Antibacterial Activity, Pharmacokinetics and Therapeutic Use in Urinary Tract Infections","volume":"23","author":"Brogden","year":"1982","journal-title":"Drugs"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Topless, R.K., Green, R., Morgan, S.L., Robinson, P.C., Merriman, T.R., and Gaffo, A.L. (2022). Folic acid and methotrexate use and their association with COVID-19 diagnosis and mortality: An analysis from the UK Biobank. medRxiv.","DOI":"10.1101\/2022.02.10.22270804"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Sheybani, Z., Dokoohaki, M.H., Negahdaripour, M., Dehdashti, M., Zolghadr, H., Moghadami, M., Masoompour, S.M., and Zolghadr, A.R. (2020). The Role of Folic Acid in the Management of Respiratory Disease Caused by COVID-19. ChemRxiv Camb. Camb. Open Engag.","DOI":"10.26434\/chemrxiv.12034980"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Meisel, E., Efros, O., Bleier, J., Halevi, T.B., Segal, G., Rahav, G., Leibowitz, A., and Grossman, E. (2021). Folate Levels in Patients Hospitalized with Coronavirus Disease 2019. Nutrients, 13.","DOI":"10.3390\/nu13030812"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"198469","DOI":"10.1016\/j.virusres.2021.198469","article-title":"The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models","volume":"302","author":"Stegmann","year":"2021","journal-title":"Virus Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1038\/s41467-021-21903-z","article-title":"SARS-CoV-2 hijacks folate and one-carbon metabolism for viral replication","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00894-022-05185-w","article-title":"Repurposing benzbromarone as antifolate to develop novel antifungal therapy for Candida albicans","volume":"28","author":"Mujwar","year":"2022","journal-title":"J. Mol. Model."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/19\/6229\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:37:11Z","timestamp":1760143031000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/19\/6229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,22]]},"references-count":90,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["molecules27196229"],"URL":"https:\/\/doi.org\/10.3390\/molecules27196229","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,22]]}}}